EGFR signaling promotes resistance to CHK1 inhibitor prexasertib in triple negative breast cancer

Abstract

Aim: Innate resistance to the CHK1 inhibitor prexasertib has been described, but resistance mechanisms are not understood. We aimed to determine the role epidermal growth factor receptor (EGFR) plays in innate resistance to prexasertib in triple negative breast cancer (TNBC).

Methods: Using a panel of pre-clinical TNBC cell lines, we measured the sensitivity to prexasertib. We examined the effect activation of EGFR had on prexasertib sensitivity. We measured the synergy of dual blockade of EGFR with erlotinib and CHK1 with prexasertib in TNBC cell lines and xenografts.

Results: EGFR overexpression and activation increased resistance to CHK1 inhibition by prexasertib. EGFR promoted the phosphorylation of BCL2-associated agonist of cell death (BAD), inactivating its pro-apoptotic functions. Inhibition of EGFR reversed BAD phosphorylation, increasing sensitivity to prexasertib.

Conclusion: The use of prexasertib as a monotherapy in TNBC has been limited due to modest clinical responses. We demonstrated that EGFR activation contributes to innate resistance to prexasertib in TNBC and potentially other cancers. EGFR expression status should be considered in clinical trials examining prexasertib’s use as a monotherapy or combination therapy.

Keywords

Triple negative breast cancer / CHK1 / replication / apoptosis / drug resistance / epidermal growth factor receptor / mitogenic signaling

References

[1] Cleary JM,Shapiro GI.Biomarker-guided development of DNA repair inhibitors..Mol Cell2020;78:1070-85 PMCID:PMC7316088

[2] Ronco C,Demange L.ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells..Medchemcomm2017;8:295-319 PMCID:PMC6072143

[3] Kim H,Ragland R.Targeting the ATR/CHK1 axis with PARP Inhibition results in tumor regression in BRCA-mutant ovarian cancer models..Clin Cancer Res2017;23:3097-108 PMCID:PMC5474193

[4] Yazinski SA,Buisson R.ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells..Genes Dev2017;31:318-32 PMCID:PMC5358727

[5] Parmar K,Lazaro JB.The CHK1 Inhibitor prexasertib exhibits monotherapy activity in high-grade serous ovarian cancer models and sensitizes to PARP inhibition..Clin Cancer Res2019;25:6127-40 PMCID:PMC6801076

[6] King C,McNeely S.LY2606368 causes replication catastrophe and antitumor effects through CHK1-dependent mechanisms..Mol Cancer Ther2015;14:2004-13

[7] Lee JM,Zimmer A.Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study..Lancet Oncol2018;19:207-15 PMCID:PMC7366122

[8] Lowery CD,Renschler M.Broad spectrum activity of the checkpoint kinase 1 inhibitor prexasertib as a single agent or chemopotentiator across a range of preclinical pediatric tumor models..Clin Cancer Res2019;25:2278-89 PMCID:PMC6445779

[9] Lowery CD,Dowless M.The checkpoint kinase 1 inhibitor prexasertib induces regression of preclinical models of human neuroblastoma..Clin Cancer Res2017;23:4354-63

[10] Bryant C,Massey AJ.Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers..BMC Cancer2014;14:570 PMCID:PMC4137066

[11] Choi C,Park S.Checkpoint kinase 1 (CHK1) inhibition enhances the sensitivity of triple-negative breast cancer cells to proton irradiation via Rad51 downregulation..Int J Mol Sci2020;21:2691 PMCID:PMC7215565

[12] Ma CX,Li S.Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models..J Clin Invest2012;122:1541-52 PMCID:PMC3314455

[13] Mani C,Lingareddy J.Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells..Breast Cancer Res2019;21:104 PMCID:PMC6729044

[14] Gatti-Mays ME,Soltani SN.A phase II single arm pilot study of the CHK1 inhibitor prexasertib (LY2606368) in BRCA wild-type, advanced triple-negative breast cancer..Oncologist2020;doi: 10.1634/theoncologist.2020-0491

[15] Booth L,Ridder T.PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells..Cancer Biol Ther2013;14:458-65 PMCID:PMC3672190

[16] Lee HJ,Pham V.Ras-MEK signaling mediates a critical Chk1-dependent DNA damage response in cancer cells..Mol Cancer Ther2017;16:694-704

[17] Gonzalez-Conchas GA,Hernandez-Barajas D.Epidermal growth factor receptor overexpression and outcomes in early breast cancer: a systematic review and a meta-analysis..Cancer Treat Rev2018;62:1-8

[18] Liu D,Yuan Z.EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray..Med Oncol2012;29:401-5

[19] Rimawi MF,Weiss HL.Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes..Cancer2010;116:1234-42 PMCID:PMC2829330

[20] Chou TC.Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies..Pharmacol Rev2006;58:621-81

[21] Sonavane M,Andrews JF,Gassman NR.Camptothecin efficacy to poison Top1 is altered by bisphenol A in mouse embryonic fibroblasts..Chem Res Toxicol2018;31:510-9 PMCID:PMC6374779

[22] Yip C,Somja J.MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib..Br J Cancer2017;116:742-51 PMCID:PMC5355928

[23] Schottle J,Volz C.Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer..Oncotarget2015;6:38458-68 PMCID:PMC4770714

[24] She QB,Ye Q.The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells..Cancer Cell2005;8:287-97 PMCID:PMC3203692

[25] Nair J,Murai J.Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer..Oncogene2020;39:5520-35 PMCID:PMC7426265

[26] Zeng L,Cooper TS,Yang ES.Combining Chk1/2 inhibition with cetuximab and radiation enhances in vitro and in vivo cytotoxicity in head and neck squamous cell carcinoma..Mol Cancer Ther2017;16:591-600 PMCID:PMC5560482

[27] Park HS,Kim EJ.High EGFR gene copy number predicts poor outcome in triple-negative breast cancer..Modern Pathol2014;27:1212-22

[28] Matsuo T,Ishida K.Analysis of the anti-tumor effect of cetuximab using protein kinetics and mouse xenograft models..BMC Res Notes2011;4:140 PMCID:PMC3118158

[29] Kimple RJ,Cox AD.Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status..Clin Cancer Res2010;16:912-23 PMCID:PMC2818631

[30] Andersson MK.Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib..Cancer Cell Int2008;8:1 PMCID:PMC2235833

[31] Pahl JH,Buddingh EP.Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma..Clin Cancer Res2012;18:432-41